No Data
West Pharmaceutical Servs Shares Are Trading Higher After Barclays Upgraded the Stock From Equal-Weight to Overweight Rating and Raised Its Price Target From $310 to $400.
This Brady Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Barclays Upgrades West Pharmaceutical Services(WST.US) to Buy Rating, Raises Target Price to $400
Barclays Upgrades West Pharmaceutical Services to Overweight From Equalweight, Adjusts PT to $400 From $310
These 10 Large-cap U.S. Healthcare Companies Carry the Market's Most Expensive Valuations
Analysts Offer Insights on Healthcare Companies: West Pharmaceutical Services (WST) and MAIA Biotechnology, Inc. (MAIA)